Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: Implications for therapy

Journal of the National Cancer Institute

Volumn 100, Issue 7, 2008, Pages 502-512

  Wang, Jun ^a,c   Seethala, Raja R ^a   Zhang, Qing ^a   Gooding, William ^b   Van Waes, Carter ^d   Hasegawa, Hitoshi ^e   Ferris, Robert L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Biostatistics Facility   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^e EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CISPLATIN; LIPOCORTIN 5; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; ANTINEOPLASTIC AGENT; CCL19 PROTEIN, HUMAN; CCL21 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMAZAN; MTT FORMAZAN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; ADULT; AGED; ANIMAL; AUTOCRINE EFFECT; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PARACRINE SIGNALING; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; CARCINOMA, SQUAMOUS CELL; CHEMOKINE CCL19; CHEMOKINE CCL21; CISPLATIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FORMAZANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PARACRINE COMMUNICATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CCR7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 41749086697     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn059     Document Type: Article

References (45)

1. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18(1):217-242.
2. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-56.
3. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119(9):2026-2039.
4. Wang J, Xi L, Hunt JL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 2004;64(5):1861-1866.
5. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003;105(2):186-189.
6. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res. 2004;10(7):2351-2358.
7. Pilkington KR, Clark-Lewis I, McColl SR. Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/MIP-3beta antagonist. J Biol Chem. 2004;279 (39):40276-40282.
8. Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 2004;104(3):619-625.
9. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277(51):49481-49487.
10. Tosi L, Rinaldi E, Carinci F, et al. Akt, protein kinase C, and mitogen-activated protein kinase phosphorylation status in head and neck squamous cell carcinoma. Head Neck. 2005;27(2):130-137.
11. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer. 2002;99(4):538-548.
12. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003;102(3):1028-1034.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
14. Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008;139:135-152.
15. Wang J, Zhang X, Thomas SM, et al. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 2005.
16. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007;67(17):8240- 8247.
17. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effect or cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989;49(18):5167-5175.
18. Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer. 1999;82(3):377-384.
19. Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102(2):244-251.
20. Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res. 2004;10(5):1625-1632.
21. Wang J, Zhang X, Thomas SM, et al. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 2005;24(38):5897-5904.
22. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol. 2003;170(1):588-596.
23. Hathaway B, Landsittel DP, Gooding W, et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope. 2005;115(3):522-527.
24. Nakano H, Gunn MD. Gene duplications at the chemokine locus on mouse chromosome 4: multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1 ligand chemokine genes in the plt mutation. J Immunol. 2001;166(1):361-369.
25. Nakano H, Tamura T, Yoshimoto T, et al. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol. 1997;27(1):215-221.
26. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999;189(3):451-460.
27. Wang J, Murakami T, Hakamata Y, et al. Gene gun-mediated oral mucosal transfer of interleukin 12 cDNA coupled with an irradiated melanoma vaccine in a hamster model: successful treatment of oral melanoma and distant skin lesion. Cancer Gene Therapy. 2001;8(10):705-712.
28. Mori S, Nakano H, Aritomi K, Wang CR, Gunn MD, Kakiuchi T. Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J Exp Med. 2001;193(2):207-218.
29. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091-2098.
30. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944.
31. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23(2):254-266.
32. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006;6(3):231-241.
33. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-850.
34. Okada T, Cyster JG. CC chemokine receptor 7 contributes to Gi-dependent T cell motility in the lymph node. J Immunol. 2007;178(5):2973-2978.
35. Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL. CCR7 mediates inflammation-associated tumor progression. Immunol Res. 2006;36(1-3):61-72.
36. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93(21):1638-1643.
37. Drayton DL, Bonizzi G, Ying X, Liao S, Karin M, Ruddle NH. I kappa B kinase complex alpha kinase activity controls chemokine and high endothelial venule gene expression in lymph nodes and nasal-associated lymphoid tissue. J Immunol. 2004;173(10):6161-6168.
38. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol. 2003;13(2):107-114.
39. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22(21):3243-3251.
40. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-567.
41. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol. 1999;9(11):601-604.
42. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol. 2000;20(5):1626-1638.
43. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet. 1993;4(1):42-46.
44. Kijima T, Niwa H, Steinman RA, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002;13(8):355-362.
45. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54.